ATE174795T1 - Verfahren zur regulierung der sexuellen reaktion beim menschen - Google Patents

Verfahren zur regulierung der sexuellen reaktion beim menschen

Info

Publication number
ATE174795T1
ATE174795T1 AT94925240T AT94925240T ATE174795T1 AT E174795 T1 ATE174795 T1 AT E174795T1 AT 94925240 T AT94925240 T AT 94925240T AT 94925240 T AT94925240 T AT 94925240T AT E174795 T1 ATE174795 T1 AT E174795T1
Authority
AT
Austria
Prior art keywords
regulating
sexual response
human beings
response
sexual
Prior art date
Application number
AT94925240T
Other languages
English (en)
Inventor
Adrian W Zorgniotti
Diane-Marie Gioco
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22311403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE174795(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zonagen Inc filed Critical Zonagen Inc
Application granted granted Critical
Publication of ATE174795T1 publication Critical patent/ATE174795T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Control Of Fluid Pressure (AREA)
  • Percussion Or Vibration Massage (AREA)
  • Medicines Containing Plant Substances (AREA)
AT94925240T 1993-08-13 1994-08-10 Verfahren zur regulierung der sexuellen reaktion beim menschen ATE174795T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10643493A 1993-08-13 1993-08-13

Publications (1)

Publication Number Publication Date
ATE174795T1 true ATE174795T1 (de) 1999-01-15

Family

ID=22311403

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925240T ATE174795T1 (de) 1993-08-13 1994-08-10 Verfahren zur regulierung der sexuellen reaktion beim menschen

Country Status (16)

Country Link
US (1) US5565466A (de)
EP (1) EP0714300B1 (de)
JP (1) JP3782101B2 (de)
KR (1) KR100391025B1 (de)
CN (1) CN1103589C (de)
AT (1) ATE174795T1 (de)
BR (1) BR9407250A (de)
CA (1) CA2169071C (de)
DE (1) DE69415535T2 (de)
DK (1) DK0714300T3 (de)
ES (1) ES2127409T3 (de)
GR (1) GR3029500T3 (de)
NO (1) NO311785B1 (de)
NZ (1) NZ271567A (de)
WO (1) WO1995005172A1 (de)
ZA (1) ZA946123B (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6387407B1 (en) 1995-09-29 2002-05-14 L.A.M. Pharmaceutical Corporation Topical drug preparations
US5897880A (en) 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6323211B1 (en) * 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
FR2748658B1 (fr) * 1996-05-15 2000-08-18 Biotec Centre Sa Utilisation de composes du type "alpha-bloquants" notamment le moxisylyte et/ou ses derives pour le traitement de dysfonctionnements erectiles par voie transmucosale balanique
JP2000516117A (ja) * 1996-08-09 2000-12-05 ウロメトリックス・インコーポレイテッド 男性不能症診断超音波システム
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
DK0996447T3 (da) * 1997-05-19 2006-11-13 Zonagen Inc Kombinationsbehandling til modulation af det humane seksuelle respons
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
EP1535611A3 (de) * 1997-06-23 2009-09-16 Strakan International Limited Microdosistherapie von Gefässbedingten Erscheinungen durch NO-Donoren
FR2765483B1 (fr) * 1997-07-04 2000-02-04 Philippe Gorny Medicament destine a traiter les dysfonctions erectiles
CA2295595A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6251076B1 (en) 1997-08-01 2001-06-26 Urometrics Inc. Male impotence diagnostic ultrasound system
US5947901A (en) 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5919436A (en) * 1997-09-25 1999-07-06 The Board Of Regents Of The University Of Oklahoma Method of lightening skin
US6110448A (en) * 1997-09-25 2000-08-29 The Board Of Regents Of The University Of Oklahoma Method for causing skin lightening
US5879665A (en) * 1997-09-25 1999-03-09 The Board Of Regents Of The University Of Oklahoma Composition for causing skin lightening
GB9720797D0 (en) * 1997-09-30 1997-12-03 Rhodes John Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US20050070516A1 (en) * 1997-10-28 2005-03-31 Vivus Inc. As-needed administration of an androgenic agent to enhance female desire and responsiveness
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction
US20040044080A1 (en) * 1997-10-28 2004-03-04 Place Virgil A. Treatment of dyspareunia with topically administered nitroglycerin formulations
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
AUPP010397A0 (en) * 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
AU2318599A (en) 1998-01-13 1999-08-02 Urometrics, Inc. Devices and methods for monitoring female arousal
GB9802078D0 (en) * 1998-01-30 1998-03-25 Futura Medical Limited Preparation for treatment of erectile dysfunction
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
FR2774593B1 (fr) * 1998-02-12 2000-05-05 Philippe Gorny Obtention d'un medicament destine a combattre les dysfonctions sexuelles feminines
FR2774594A1 (fr) * 1998-02-12 1999-08-13 Philippe Gorny Medicament destine notamment a prevenir ou traiter les dysfonctions erectiles
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6365590B1 (en) 1998-05-26 2002-04-02 Saint Louis University Compounds, compositions and methods for treating erectile dysfunction
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
CA2340206A1 (en) * 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti-pressor agents for vascular remodeling in genital dysfunction
US6482426B1 (en) * 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6486207B2 (en) * 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
KR20020015310A (ko) * 1999-04-06 2002-02-27 로버트 엘. 로브 신체적인 성적반응을 변화시키는 방법
US6214849B1 (en) 1999-04-29 2001-04-10 Lupin Laboratories Limited Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
IT1312310B1 (it) 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
US6405219B2 (en) 1999-06-22 2002-06-11 F5 Networks, Inc. Method and system for automatically updating the version of a set of files stored on content servers
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
DE60131644T2 (de) * 2000-05-09 2008-10-30 Nitromed, Inc., Lexington Infrarotthermographie und behandlung von sexuellen dysfunktionen
US20040137081A1 (en) * 2003-01-13 2004-07-15 Peter Rohdewald Attaining sexual wellness and health of the sexual vascular system with proanthocyanidins
US6737084B2 (en) 2000-06-27 2004-05-18 Qualilife Compositions and methods for enhancing or treating female sexual response
FI20002755A0 (fi) * 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
EP1365740A1 (de) * 2001-02-08 2003-12-03 Pharmacia Corporation Arzneizmittel mit schnellem wirkungseintritt zur behandlung von sexuellen dysfunktion
WO2002069906A2 (en) 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US20030158184A1 (en) * 2001-12-21 2003-08-21 Garvey David S. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
EP1750766B1 (de) * 2004-05-11 2013-07-03 Emotional Brain B.V. Pharmazeutische Formulierungen und ihre Verwendungen bei der Behandlung von weiblicher sexueller Dysfunktion
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) * 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
AU2009301391B2 (en) * 2008-10-10 2015-10-22 Medicaltree Patent Ltd Stimulation of penis erection
US8939889B1 (en) 2013-08-22 2015-01-27 Coloplast A/S Pump bulb for an implantable penile prosthetic
US11622730B2 (en) * 2014-11-17 2023-04-11 Rochester Institute Of Technology Pulse wave velocity, arterial compliance, and blood pressure

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943246A (en) * 1972-07-10 1976-03-09 Sandoz Ltd. Organic compounds
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4885173A (en) * 1985-05-01 1989-12-05 University Of Utah Methods and compositions for noninvasive dose-to-effect administration of drugs with cardiovascular or renal vascular activities
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
WO1990015583A1 (fr) * 1989-06-16 1990-12-27 Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki Dispositif de traitement de la faiblesse sexuelle chez l'homme
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence

Also Published As

Publication number Publication date
KR100391025B1 (ko) 2003-10-04
AU7523894A (en) 1995-03-14
DE69415535T2 (de) 1999-06-17
CN1103589C (zh) 2003-03-26
NO311785B1 (no) 2002-01-28
CN1128950A (zh) 1996-08-14
GR3029500T3 (en) 1999-05-28
JP3782101B2 (ja) 2006-06-07
EP0714300A1 (de) 1996-06-05
NO960549D0 (no) 1996-02-12
AU696815B2 (en) 1998-09-17
ZA946123B (en) 1995-03-20
EP0714300B1 (de) 1998-12-23
DK0714300T3 (da) 1999-08-23
KR960703588A (ko) 1996-08-31
CA2169071C (en) 2008-10-21
ES2127409T3 (es) 1999-04-16
NZ271567A (en) 1997-12-19
BR9407250A (pt) 1996-09-24
CA2169071A1 (en) 1995-02-23
DE69415535D1 (de) 1999-02-04
NO960549L (no) 1996-04-12
WO1995005172A1 (en) 1995-02-23
US5565466A (en) 1996-10-15
EP0714300A4 (de) 1996-07-24
JPH09501677A (ja) 1997-02-18

Similar Documents

Publication Publication Date Title
ATE174795T1 (de) Verfahren zur regulierung der sexuellen reaktion beim menschen
ATE185695T1 (de) Verfahren und formulierungen zur modulation der sexualreaktion beim menschen
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
DE69217993D1 (de) Verfahren zur erhoehung der stabilitaet von polyesteramiden
DE69214610D1 (de) Verfahren zur Behandlung von Erdgas
GT199500006A (es) 6 sustituidos de acido micofenolico y sus derivados
BG102757A (en) Methods for the treatment or vomiting and central nervous system disorders by the application of optically pure (+) norcisaprid
ATE161013T1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
PT81991A (fr) Procede pour l'obtention de derives analogues de la pepstatine inhibidors de la renine et de proteases acides
PH21102A (en) Improvements in or relating to benzothiophene derivatives as antiastmatic agents
MX9302116A (es) Compuestos azabiciclo.
DE69325452D1 (de) Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
SG50505A1 (en) Melatonin derivatives for use in treating sleep disorders
ES2096727T5 (es) Productos cosmeticos y farmaceuticos que contienen extensinas.
NO307364B1 (no) Anvendelse av melatoninderivater
DE59309740D1 (de) Lyopilisierte, wirkstoffhaltige emulsion
DE69321577D1 (de) Verfahren zur herstellung von diestern von naphtalendicarbonsäuren
ATE82850T1 (de) Verwendung von 2-pyrimidinyl-1-piperazinderivaten.
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
NO995132L (no) Fremgangsmåte for reduksjon av fibrinogen
DK0741746T3 (da) Thymosin alpha 1-analoger
NO944429D0 (no) Enantiomere dynemicinanaloger, fremgangsmåte for fremstilling samt anvendelse derav
ITTO920519A0 (it) Sussidio terapeuticodinamico per larieducazione sensitivo-motoria del-l'arto superiore in pazienti cerebrolesi.
ES1022126Y (es) "regulador perfeccionado de gas natural"

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee